Lanreotide

Somatuline DepotGI/Bone/Other

Evidence grade

AFDA-approved Rx (labeled use)

Cardiovascular · 0–5 · separate axis

Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeEndocrine / GI

MechanismLong-acting somatostatin analog; suppresses GH and IGF-1 and slows neuroendocrine tumour progression

EffectsSame axis as octreotide with a longer dosing interval

Dosing90-120 mg by deep subcutaneous injection every 4 weeks

Bottom lineStrongest data when used for its labeled indication under clinician guidance.

Batches on filenone

No tested batches on file.

Read with10

Tesamorelin Somatropin Sermorelin CJC-1295 (no DAC)Ipamorelin GHRP-2 GHRP-6 Desmopressin (DDAVP)Teriparatide (Forteo)Abaloparatide (Tymlos)

Cautions & interactions

Gallstones; glucose dysregulation; bradycardia; injection-site reactions

Alters insulin and oral diabetes medication requirements; affects ciclosporin levels.

CV 2 of 5 — Bradycardia and conduction effects are recognised; monitor in patients with existing cardiac disease.